Fenwick & West represented PACT Pharma Inc., a leading startup in the development of personalized adoptive T cell therapies designed for the eradication of solid tumors, in the intellectual property due diligence aspect of its $95 million Series B financing. Alphabet Inc.’s venture arm GV led the round, with participation from Invus Group, Canaan Partners, Casdin Capital, Wu Capital and other undisclosed investors.
The funding will be used to expand operations and begin human clinical trials next year. More information about PACT Pharma’s $95 million Series B financing can be obtained here.
The Fenwick transaction team was led by intellectual property attorneys Michael Shuster and Kevin Kabler.